On Thursday, in the course of current trade, Shares of CA, Inc. (NASDAQ:CA), climbed 0.37%, and is now trading at $ 30.13.
CA, declared it has attained Grid Tools Ltd., a leading provider of enterprise test data administration, automated test design and optimization software solutions. Terms of the transaction were not revealed.
The acquisition of privately-held Grid-Tools will enable CA Technologies to expand its DevOps portfolio with an improved focus on quality acceleration. Time consuming, manual testing and data administration have prevented enterprises from realizing the true potential of agile development and continuous delivery. Grid-Tools’ solutions allow organizations to significantly accelerate their quality lifecycle by providing greater test coverage, faster test creation and repeatable test execution for software assets, while considerably reducing the time and resources required to bring products to market.
CA, provides information technology administration software and solutions that assist organizations plan, develop, manage, and secure applications and IT infrastructure in the United States and internationally.
During Morning trade, Shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX), climbed 4.91%, and is now trading at $ 2.78.
Celator Pharmaceuticals, declared that Scott Jackson, Chief Executive Officer, will present an overview of the company at the BIO Business Forum, part of the 2015 BIO International Convention, on Wednesday June 17, 2015, at 3:15 p.m. EDT, at the Pennsylvania Convention Center, Theater 4, Philadelphia PA.
Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, in addition to molecularly targeted agents to deliver improved anti-cancer activity.
Shares of Zillow Group Inc (NASDAQ:Z), during its Thursday’s current trading session fell -1.05 %, and is now trading at $ 89.79.
The 30-year fixed mortgage rate on Zillow Mortgages is presently 3.78 percent, down one point from this time last week. The 30-year fixed mortgage rate hovered around 3.74 percent for most of the week before rising to the current rate on Tuesday.
“Rates were largely flat last week, but we don’t expect this recent stability to continue,” said Erin Lantz, vice president of mortgages at Zillow. “Rates should be more volatile this week as markets watch developments in Greece and Friday’s jobs report.”
Zillow’s real-time mortgage rates are based on thousands of custom mortgage quotes presented daily to anonymous borrowers on the Zillow Mortgages site, and reflect the most recent changes in the market. These are not marketing rates, or a weekly survey.
The rate for a 15-year fixed home loan is presently 2.93 percent, while the rate for a 5-1 adjustable-rate mortgage (ARM) is 2.80 percent.
Zillow Group, Inc. operates real estate and home-related information marketplaces on mobile and the Web in the United States. It offers a portfolio of brands and products to assist people find vital information about homes, and connect with local professionals.
Finally, ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), gained 3.53% Thursday, hitting its highest level.
ZIOPHARM Oncology, declared that Caesar J. Belbel, Executive Vice President, Chief Legal Officer and Secretary, has been designated to the added role of Chief Operating Officer, effective right away.
“Caesar has been an integral part of the ZIOPHARM senior administration team through the Company’s evolution into a leading developer of next generation immuno-oncology therapeutics,” said Laurence J. N. Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. “He has the experience and expertise, developed over a 30 year career in advising and building emerging companies, to assist ZIOPHARM prosper in its next phase of development. We expect that his leadership, corporate development and transactional experience will continue to add noteworthy value to the Company as he takes on the responsibilities of this new role.”
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
